Vera Therapeutics Inc (VERA)
37.98
+1.03
(+2.79%)
USD |
NASDAQ |
May 31, 16:00
37.98
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Research and Development Expense (TTM): 76.32M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 76.32M |
| December 31, 2023 | 78.22M |
| September 30, 2023 | 84.12M |
| June 30, 2023 | 87.67M |
| March 31, 2023 | 81.55M |
| December 31, 2022 | 68.99M |
| September 30, 2022 | 55.07M |
| Date | Value |
|---|---|
| June 30, 2022 | 38.98M |
| March 31, 2022 | 32.10M |
| December 31, 2021 | 22.48M |
| September 30, 2021 | 49.58M |
| June 30, 2021 | 47.98M |
| March 31, 2021 | 46.70M |
| December 31, 2020 | 45.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
22.48M
Minimum
Dec 2021
87.67M
Maximum
Jun 2023
58.21M
Average
52.32M
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.209B |
| Alpine Immune Sciences Inc (DELISTED) | 83.78M |
| Fate Therapeutics Inc | 139.10M |
| Mersana Therapeutics Inc | 119.68M |
| Equillium Inc | 37.51M |